Company Overview of MedImmune, LLC
MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. MedImmune, LLC has a strategic alliance with WuXi AppTec. The company was incorporated in 1987 and is based in Gaithers...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1987
Key Executives for MedImmune, LLC
Vice President of Finance
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Compensation as of Fiscal Year 2016.
MedImmune, LLC Key Developments
Medimmune Signs Licensing Agreement with Genisphere
Jun 6 16
MedImmune, LLC has entered into a license agreement with Genisphere LLC to develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with up to six MedImmune oncology molecules, as the nanoparticle configuration may help to improve targeting of the drug. Both the companies are based in the US. Under the terms of the transaction, Genisphere will receive an upfront payment, development milestones and future royalties upon MedImmune triggering an option, and development and commercialization of therapeutics stemming from the collaboration.
Regeneron Pharmaceuticals Enters into Licensing Agreement with Medimmune
Apr 6 16
Regeneron Pharmaceuticals Inc. and MedImmune, LLC have entered into a licensing agreement under which Regeneron will use MedImmune's pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibodydrug conjugates (ADCs) as potential cancer treatments. Both the companies are based in the US. Under the terms of the agreement, Regeneron will have exclusive rights to utilize MedImmune's PBD technology to develop ADCs against a number of cancer targets. MedImmune will receive an upfront payment, development and commercial milestone payments, as well as single-digit royalties on net sales of such products. MedImmune has the option to develop and commercialize certain products created with this technology in territories outside of the US.
AstraZeneca Plc. and Medimmune Announces Update on DETERMINE
Feb 29 16
AstraZeneca plc. and MedImmune announced that DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival. In addition to investigation as monotherapy for patients with mesothelioma, tremelimumab is being studied in combination with AstraZeneca's anti-PD-L1 investigational immunotherapy durvalumab in multiple tumour types, including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers. Preclinical data have suggested that targeting both PD-L1 and CTLA-4 may have additive or synergistic effects. In the recently published Study 006, combination treatment with durvalumab and tremelimumab demonstrated antitumour activity in patients with locally advanced or metastatic NSCLC, irrespective of PD-L1 status. The company noted that it will complete a full evaluation of the final DETERMINE data, which will be submitted for presentation at an upcoming medical meeting in 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|